Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action

Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established....

Full description

Saved in:
Bibliographic Details
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (206 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993562964604498
ctrlnum (CKB)5670000000391619
(oapen)https://directory.doabooks.org/handle/20.500.12854/93214
(EXLCZ)995670000000391619
collection bib_alma
record_format marc
spelling Allison, Simon J edt
Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action
Novel Anti-cancer Agents and Cellular Targets and Their Mechanism
MDPI - Multidisciplinary Digital Publishing Institute 2022
1 electronic resource (206 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established. It is apparent that inherent and acquired drug resistance are major challenges with molecular-targeted agents and that on- as well as off-target side effects can still occur. Other issues include drug metabolism by the body and safely supplying a sufficient amount of active drug to the tumor cells. There is a clear and urgent need for new molecular targets and drugs that specifically target cancer cells in different ways to existing approved drugs. This book, through a collection of eight research articles and two review articles from the Biomedicines themed Special Issue ‘Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action’, provides a snapshot of some of the diverse and exciting research approaches being taken by the cancer research community in trying to address some of these therapeutic challenges.
English
Technology: general issues bicssc
History of engineering & technology bicssc
microtubule acetylation
triple-negative breast cancer
anti-cancer agent
apoptosis
K562
8-hydroxydaidzein
autophagy
BCR-ABL
MAPK
NF-κB
c-myc
RNA interference
siRNA
oncogene
gene silencing
expression
nanosystems
Cytochrome P450
CYP1A1
CYP1B1
CYP2W1
breast cancer
prodrug
bioprecursor
duocarmycin
phortress
AQ4N
5-FU resistance
colorectal cancer
drug repurposing
Genomics of Drug Sensitivity in Cancer
Connectivity Map
anticancer drug
B-lactam steroid alkylators
synthetic lethality
poly (ADP-ribose) polymerase inhibitors
ovarian cancer
hybrid steroidal alkylating agents
migration
invasion
glioblastoma
CCN1
mesenchymal-amoeboid transition
biomarker
HepG2
Huh7
isatin sulfonamides
angiogenesis
cancer hallmarks
molecular docking
EGFR tyrosine kinase inhibitor
photon upconversion
triplet-triplet annihilation
in vivo imaging
PLGA
nanoparticles
affibody molecule
human epidermal growth factor receptor 3 (HER3)
BxPC-3
emtansine
DM1
albumin binding domain
affibody drug conjugate (AffiDC)
3-0365-5221-9
Allison, Simon J oth
language English
format eBook
author2 Allison, Simon J
author_facet Allison, Simon J
author2_variant s j a sj sja
author2_role Sonstige
title Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action
spellingShingle Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action
title_full Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action
title_fullStr Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action
title_full_unstemmed Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action
title_auth Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action
title_alt Novel Anti-cancer Agents and Cellular Targets and Their Mechanism
title_new Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action
title_sort novel anti-cancer agents and cellular targets and their mechanism(s) of action
publisher MDPI - Multidisciplinary Digital Publishing Institute
publishDate 2022
physical 1 electronic resource (206 p.)
isbn 3-0365-5222-7
3-0365-5221-9
illustrated Not Illustrated
work_keys_str_mv AT allisonsimonj novelanticanceragentsandcellulartargetsandtheirmechanismsofaction
AT allisonsimonj novelanticanceragentsandcellulartargetsandtheirmechanism
status_str n
ids_txt_mv (CKB)5670000000391619
(oapen)https://directory.doabooks.org/handle/20.500.12854/93214
(EXLCZ)995670000000391619
carrierType_str_mv cr
is_hierarchy_title Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action
author2_original_writing_str_mv noLinkedField
_version_ 1787551938360901633
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04224nam-a2201069z--4500</leader><controlfield tag="001">993562964604498</controlfield><controlfield tag="005">20231214133656.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202210s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-0365-5222-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5670000000391619</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/93214</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995670000000391619</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Allison, Simon J</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Novel Anti-cancer Agents and Cellular Targets and Their Mechanism</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (206 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established. It is apparent that inherent and acquired drug resistance are major challenges with molecular-targeted agents and that on- as well as off-target side effects can still occur. Other issues include drug metabolism by the body and safely supplying a sufficient amount of active drug to the tumor cells. There is a clear and urgent need for new molecular targets and drugs that specifically target cancer cells in different ways to existing approved drugs. This book, through a collection of eight research articles and two review articles from the Biomedicines themed Special Issue ‘Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action’, provides a snapshot of some of the diverse and exciting research approaches being taken by the cancer research community in trying to address some of these therapeutic challenges.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Technology: general issues</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">History of engineering &amp; technology</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microtubule acetylation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">triple-negative breast cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-cancer agent</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">apoptosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">K562</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">8-hydroxydaidzein</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">autophagy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BCR-ABL</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MAPK</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NF-κB</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">c-myc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RNA interference</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">siRNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncogene</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gene silencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">expression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanosystems</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cytochrome P450</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP1A1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP1B1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP2W1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">breast cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prodrug</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bioprecursor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">duocarmycin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phortress</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">AQ4N</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">5-FU resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">colorectal cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug repurposing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Genomics of Drug Sensitivity in Cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Connectivity Map</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anticancer drug</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">B-lactam steroid alkylators</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">synthetic lethality</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">poly (ADP-ribose) polymerase inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ovarian cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hybrid steroidal alkylating agents</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">migration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">invasion</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glioblastoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CCN1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mesenchymal-amoeboid transition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HepG2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Huh7</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">isatin sulfonamides</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">angiogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer hallmarks</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular docking</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">EGFR tyrosine kinase inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">photon upconversion</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">triplet-triplet annihilation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in vivo imaging</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PLGA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanoparticles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">affibody molecule</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">human epidermal growth factor receptor 3 (HER3)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BxPC-3</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">emtansine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DM1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">albumin binding domain</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">affibody drug conjugate (AffiDC)</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-5221-9</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Allison, Simon J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 06:02:20 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-11-05 21:33:14 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5340568990004498&amp;Force_direct=true</subfield><subfield code="Z">5340568990004498</subfield><subfield code="b">Available</subfield><subfield code="8">5340568990004498</subfield></datafield></record></collection>